We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+31.64%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$992M
AUM Growth
–
Cap. Flow
+$823M
Cap. Flow
% of AUM
82.96%
Top 10 Holdings %
Top 10 Hldgs %
67.13%
Holding
92
New
79
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$190M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$97.3M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$62.4M |
| 4 |
Biogen
BIIB
|
+$49.4M |
| 5 |
Gilead Sciences
GILD
|
+$41.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.43% |
| 2 | Miscellaneous | 16.86% |
| 3 | Consumer Staples | 1.78% |
| 4 | Financials | 0.72% |
| 5 | Industrials | 0.1% |
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Perceptive Advisors, which disclosed 92 positions worth $992M. Its ten largest holdings account for 67% of the portfolio.
Its largest position is Aegerion Pharmaceuticals: 3,573,426 shares worth $226M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2013 buy was Aegerion Pharmaceuticals: 3,573,426 shares worth $226M.
- Perceptive Advisors's ten largest holdings make up 67% of its $992M portfolio in Q2 2013.
- Perceptive Advisors disclosed 92 positions in Q2 2013, its first 13F filing on record.
Based on Perceptive Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.